ENTITY

PhotoCure ASA (PHO NO)

14
Analysis
Health CareNorway
PhotoCure ASA develops and produces pharmaceutical photodynamic therapy products and devices. The Company utilizes light-activated drugs in the treatment of cancer and other medical conditions. PhotoCure markets Metvix, a cream for the treatment of skin disorders, and the Curelight lamp to be used with the cream. The Company works with international research centers.
more
bullishPhotoCure ASA
01 Jun 2021 22:03Issuer-paid

Photocure - Termination of coverage

Edison Investment Research is terminating coverage on Augean (AUG), Deinove (ALDEI), Photocure (PHO), RADA Electronic Industries (RADA) and Ryvu...

Share
bullishPhotoCure ASA
13 May 2020 14:44Issuer-paid

Photocure - Buying back rights from Ipsen

Photocure has announced that it is in the process of re-acquiring the rights to Hexvix/Cysview in territories where Ipsen is currently marketing...

Share
bullishPhotoCure ASA
04 Mar 2020 18:49Issuer-paid

Photocure - Firing on all cylinders

Photocure announced very strong Q419 results, with 27% revenue growth for the Hexvix/Cysview franchise (vs Q418) to NOK58.8m, an acceleration from...

Share
bullishPhotoCure ASA
13 Nov 2019 22:36Issuer-paid

Photocure - US sales up 53% compared to last year

Photocure announced Q319 results, with 18% revenue growth for the Hexvix/Cysview franchise (vs Q318) to NOK51.1m. US sales of NOK25.2m were up 53%...

Share
bullishPhotoCure ASA
22 Nov 2018 21:08Issuer-paid

Photocure - Strong revenue growth

Photocure has announced results for Q318, with 25% revenue growth compared to Q317. Revenues grew strongly in the US, where Hexvix/Cysview sales...

Share
No more insights
x